Literature DB >> 2364385

Interaction of rhizoxin with bovine brain tubulin.

A S Sullivan1, V Prasad, M C Roach, M Takahashi, S Iwasaki, R F Ludueña.   

Abstract

Rhizoxin is an antitumor drug prepared from the fungus Rhizopus chinensis. It is an inhibitor of microtubule assembly and a potent competitive inhibitor of the binding of tubulin of ansamitocin P-3, a maytansine analogue. Rhizoxin also weakly inhibits vinblastine binding to tubulin. We have previously found that maytansine and vinblastine differ strikingly from each other in many ways, including their effects on tubulin sulfhydryl groups and on tubulin decay. Since the structure of rhizoxin is very different from that of vinblastine and only slightly resembles that of maytansine, we decided to compare its interaction with tubulin with those of the other two drugs, using systems which discriminate between the effects of the latter two drugs. We found that rhizoxin acts like maytansine in that it completely prevents formation of an intrachain cross-link in beta-tubulin by N,N'-ethylenebis(iodoacetamide), whereas vinblastine only partially inhibits this. Half-maximal inhibition of formation of this cross-link was observed at 2.5 microM rhizoxin. We found previously that the rate of binding of tubulin to the fluorescent probe bis(8-anilinonaphthalene 1-sulfonate) is a good indicator of tubulin decay and that vinblastine strongly inhibits this, whereas maytansine has no effect. We here report that rhizoxin acts like maytansine in that it has no effect on decay. Thus, despite the fact that its resemblance to maytansine is small, rhizoxin appears to interact with tubulin in very much the same way as does maytansine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364385

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs.

Authors:  Manu Lopus
Journal:  Mol Cell Biochem       Date:  2013-06-07       Impact factor: 3.396

Review 3.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

4.  Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

Authors:  H L McLeod; L S Murray; J Wanders; A Setanoians; M A Graham; N Pavlidis; B Heinrich; W W ten Bokkel Huinink; D J Wagener; S Aamdal; J Verweij
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

5.  Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

Authors:  M García-Rocha; M D García-Gravalos; J Avila
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

6.  Ring-Closing Metathesis Approaches towards the Total Synthesis of Rhizoxins.

Authors:  Marc Liniger; Christian M Neuhaus; Karl-Heinz Altmann
Journal:  Molecules       Date:  2020-10-02       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.